Skip to main content
. 2022 Sep 14;14(18):4464. doi: 10.3390/cancers14184464

Figure 1.

Figure 1

IgG antibody titres against S, M and N proteins. Backgrounds from paired technical controls were removed from each sample. (A–C) S-specific IgG antibody titres in sera (1:800) from healthy donors and oncologic patients. (D–F) M-specific IgG antibody titres in sera (1:80) from healthy donors and oncologic patients. (G–I) N-specific IgG antibody titres in sera (1:250) from healthy donors and oncologic patients. (A,B,D,E,G,H) Non-parametric Kruskal–Wallis test was used for multiple comparisons followed by Dunn’s test for selected pair-wise comparisons. (C,F,I) Pair-wise comparisons were performed using the Mann–Whitney U-test. H-N/N, non-vaccinated, non-COVID-19 donors; H-CoV, healthy donors with previous COVID-19 infection; H-V, vaccinated healthy donor; H-CoV-V, vaccinated healthy donor with previous COVID-19; O-CoV, oncologic patient with previous COVID-19; O-V, vaccinated oncologic patients; O-CoV-V, vaccinated oncologic patients with previous COVID-19; *, **, *** and **** indicate significant (p < 0.05), very significant (p < 0.01), highly significant (p < 0.001) and very highly significant (p < 0.0001) differences, respectively.